DAUNORUBICIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Daunorubicin Hydrochloride, and what generic alternatives are available?
Daunorubicin Hydrochloride is a drug marketed by Fresenius Kabi Usa, Hikma, Hisun Pharm Hangzhou, Meitheal, and Teva Parenteral. and is included in seven NDAs.
The generic ingredient in DAUNORUBICIN HYDROCHLORIDE is daunorubicin hydrochloride. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the daunorubicin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Daunorubicin Hydrochloride
A generic version of DAUNORUBICIN HYDROCHLORIDE was approved as daunorubicin hydrochloride by HIKMA on January 30th, 1998.
Summary for DAUNORUBICIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 94 |
Clinical Trials: | 372 |
Patent Applications: | 4,953 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in DAUNORUBICIN HYDROCHLORIDE? | DAUNORUBICIN HYDROCHLORIDE excipients list |
DailyMed Link: | DAUNORUBICIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DAUNORUBICIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Uwe Platzbecker | Phase 2 |
Gilead Sciences | Phase 2 |
Kura Oncology, Inc. | Phase 1 |
Pharmacology for DAUNORUBICIN HYDROCHLORIDE
Drug Class | Anthracycline Topoisomerase Inhibitor |
Mechanism of Action | Topoisomerase Inhibitors |